Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2025-03-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（一）
Board/Management Information Classification · 95% confidence The document is a formal statement from the board of directors of Chongqing Boteng Pharmaceutical Technology Co., Ltd. nominating an independent director candidate. It includes detailed declarations about the candidate's qualifications, compliance with relevant laws and regulations, and independence criteria. The content focuses on board/management information, specifically the nomination of a board member, rather than financial results, audit, or other report types. There is no indication of financial data, earnings, or regulatory filings beyond the nomination statement. Therefore, this document fits best under the category of Board/Management Information (MANG). The document length is about 5180 characters, which is sufficient for a detailed nomination statement rather than a brief announcement.
2025-03-28 Chinese
独立董事2024年度述职报告（庞金伟）
Board/Management Information Classification · 95% confidence The document is an independent director's annual performance report for the year 2024, detailing the director's duties, meeting attendance, communication with audit committees, and other governance activities. It is a detailed narrative report about the director's role and activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it a regulatory filing or announcement of voting results. The content fits best under Board/Management Information (MANG) as it relates to the activities and responsibilities of a board member (independent director). The document length is 3296 characters, which is consistent with a detailed report but not a full annual report or earnings release. Therefore, the classification is MANG with high confidence.
2025-03-28 Chinese
关于2024年度拟不进行利润分配的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the company's 2024 profit distribution plan, specifically stating that no profit distribution (dividends or share capital increases) will be made for the year 2024. It includes details about the audited net loss, retained earnings, and the rationale for not distributing profits. The document references board and supervisory committee meeting resolutions approving the plan and states that the plan will be submitted to the shareholders' meeting for approval. The document is relatively short (2073 characters) and primarily serves as a formal announcement of the profit distribution decision rather than a full financial report or detailed annual report. It does not contain comprehensive financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like Earnings Release or Management Reports, as it focuses on dividend policy and profit distribution. Therefore, the most appropriate classification is Notice of Dividend Amount (DIV), as it announces the company's dividend distribution decision for the fiscal year.
2025-03-28 Chinese
关于2023年员工持股计划锁定期届满的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the expiration of the lock-up period of the 2023 employee stock ownership plan. It details the stock purchase completion, lock-up period dates, subsequent arrangements after the lock-up period, and the plan's duration, changes, and termination conditions. The document is relatively short (1816 characters) and serves as a notification about the status and next steps of the employee stock ownership plan rather than a detailed financial report or data. It does not contain financial statements or detailed financial analysis but rather compliance and procedural information about the stock plan. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about the employee stock ownership plan status and compliance with disclosure obligations, not a full report or financial supplement.
2025-02-27 Chinese
第五届董事会第三十次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 30th extraordinary meeting of the 5th Board of Directors of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details voting results on investment decisions, cash management, and the establishment of a donation management system. The content focuses on board decisions and governance matters rather than financial results or reports. The document length is short (1273 characters) and it is an announcement of board meeting resolutions, not a full report or financial statement. Therefore, it fits best under Board/Management Information (MANG).
2025-02-26 Chinese
关于参与认购投资基金份额的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding its participation in subscribing to investment fund shares managed by Shenzhen Songhe Capital Management Co., Ltd. It details the transaction overview, information about the fund and its partners, the partnership agreement, related party relationships, and risk disclosures. The document is a formal announcement of a capital investment activity by the company, specifically about investing in a private equity fund. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report like an Annual Report or Interim Report, nor is it a regulatory certification or voting result. The content fits best under the category of Capital/Financing Update (CAP), as it relates to the company's financing activities and capital deployment into an investment fund.
2025-02-26 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.